WGS

SEC source: 0001209191-21-059756 · doc4.xml · derivative · entry 1

Ro Isaac · CIK 0001873463 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 578,704

Underlying: Class A Common Stock · 578,704 shares

Expires 2031-09-30

F1 · derivative.exercise_date: 1/8th of the total shares vest on October 25, 2021, 1/16th of the total shares vest on November 8, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on February 8, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-059754 · doc4.xml · derivative · entry 2

Clark Daniel Emmett · CIK 0001874449 · Secretary and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,049

Underlying: Class A Common Stock · 63,049 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F1 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-059754 · doc4.xml · derivative · entry 1

Clark Daniel Emmett · CIK 0001874449 · Secretary and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,033

Underlying: Class A Common Stock · 42,033 shares

Expires 2031-09-30

F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-059755 · doc4.xml · derivative · entry 2

Schadt Eric · CIK 0001873468 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,260,999

Underlying: Class A Common Stock · 1,260,999 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F1 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-059755 · doc4.xml · derivative · entry 1

Schadt Eric · CIK 0001873468 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 840,666

Underlying: Class A Common Stock · 840,666 shares

Expires 2031-09-30

F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-059760 · doc4.xml · derivative · entry 2

Assad Shawn · CIK 0001873887 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,322

Underlying: Class A Common Stock · 167,322 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F1 · derivative.exercise_date: 1/16th of the total shares vest on October 25, 2021 and November 10, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F1 · derivative.expiration_date: 1/16th of the total shares vest on October 25, 2021 and November 10, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-059760 · doc4.xml · derivative · entry 1

Assad Shawn · CIK 0001873887 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,830

Underlying: Class A Common Stock · 96,830 shares

Expires 2031-09-30

F1 · derivative.exercise_date: 1/16th of the total shares vest on October 25, 2021 and November 10, 2021, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on May 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-059759 · doc4.xml · derivative · entry 2

White Karen Ann · CIK 0001874118 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,057

Underlying: Class A Common Stock · 72,057 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F1 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-059759 · doc4.xml · derivative · entry 1

White Karen Ann · CIK 0001874118 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,038

Underlying: Class A Common Stock · 48,038 shares

Expires 2031-09-30

F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-059758 · doc4.xml · derivative · entry 2

Saad Kareem · CIK 0001873805 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 288,228

Underlying: Class A Common Stock · 288,228 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F1 · derivative.exercise_date: 3/16th of the total shares vest on October 25, 2021, 1/16th of the total shares vest on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F1 · derivative.expiration_date: 3/16th of the total shares vest on October 25, 2021, 1/16th of the total shares vest on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-059758 · doc4.xml · derivative · entry 1

Saad Kareem · CIK 0001873805 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 192,152

Underlying: Class A Common Stock · 192,152 shares

Expires 2031-09-30

F1 · derivative.exercise_date: 3/16th of the total shares vest on October 25, 2021, 1/16th of the total shares vest on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-059753 · doc4.xml · derivative · entry 2

Prentice Anthony · CIK 0001873901 · Chief Product Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,049

Underlying: Class A Common Stock · 63,049 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F1 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-059753 · doc4.xml · derivative · entry 1

Prentice Anthony · CIK 0001873901 · Chief Product Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,033

Underlying: Class A Common Stock · 42,033 shares

Expires 2031-09-30

F1 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on July 25, 2021 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-059876 · doc4.xml · derivative · entry 1

Assad Shawn · CIK 0001873887 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,776

Underlying: Class A Common Stock · 34,776 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: 25% of the total shares vest on October 1, 2022, and thereafter vests as to 75% of the total shares underlying the award in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F2 · derivative.expiration_date: 25% of the total shares vest on October 1, 2022, and thereafter vests as to 75% of the total shares underlying the award in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-062559 · doc4a.xml · derivative · entry 1

Assad Shawn · CIK 0001873887 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,776

Underlying: Class A Common Stock · 34,776 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.

F2 · derivative.exercise_date: This Form 4 is being amended to correct the vesting schedule as to 25% of the total shares vest on October 1, 2023, and thereafter as to 75% of the total shares underlying the award in quarterly installments until fully vested on October 1, 2026, subject to the Reporting Person's continued service to the Issuer on each vesting date.

F2 · derivative.expiration_date: This Form 4 is being amended to correct the vesting schedule as to 25% of the total shares vest on October 1, 2023, and thereafter as to 75% of the total shares underlying the award in quarterly installments until fully vested on October 1, 2026, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-048230 · doc4.xml · derivative · entry 3

Coffin James · CIK 0001873883 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 480,657

Underlying: Class A Common Stock · 480,657 shares

Expires 2030-02-17

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F1 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-048230 · doc4.xml · derivative · entry 2

Coffin James · CIK 0001873883 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 332,963

Underlying: Class A Common Stock · 332,963 shares

Expires 2030-02-17

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F1 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-048230 · doc4.xml · derivative · entry 1

Coffin James · CIK 0001873883 · President and COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,167,093

Underlying: Class A Common Stock · 2,167,093 shares

Expires 2027-08-30

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F1 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-048225 · doc4.xml · derivative · entry 3

Clark Daniel Emmett · CIK 0001874449 · Secretary and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 401,767

Underlying: Class A Common Stock · 401,767 shares

Expires 2030-02-17

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F3 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-048225 · doc4.xml · derivative · entry 2

Clark Daniel Emmett · CIK 0001874449 · Secretary and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,760

Underlying: Class A Common Stock · 13,760 shares

Expires 2030-02-17

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F1 · derivative.exercise_date: This option is fully vested.

SEC source: 0001209191-21-048225 · doc4.xml · derivative · entry 1

Clark Daniel Emmett · CIK 0001874449 · Secretary and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,114,504

Underlying: Class A Common Stock · 1,114,504 shares

Expires 2027-06-19

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F1 · derivative.exercise_date: This option is fully vested.

SEC source: 0001209191-21-048228 · doc4.xml · derivative · entry 5

Schadt Eric · CIK 0001873468 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,311,488

Underlying: Class A Common Stock · 2,311,488 shares

Expires 2030-02-17

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F3 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-048228 · doc4.xml · derivative · entry 4

Schadt Eric · CIK 0001873468 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 960,472

Underlying: Class A Common Stock · 960,472 shares

Expires 2029-10-16

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F3 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-048228 · doc4.xml · derivative · entry 3

Schadt Eric · CIK 0001873468 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 401,699

Underlying: Class A Common Stock · 401,699 shares

Expires 2029-10-16

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F3 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-048228 · doc4.xml · derivative · entry 2

Schadt Eric · CIK 0001873468 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,264,674

Underlying: Class A Common Stock · 2,264,674 shares

Expires 2027-05-31

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F1 · derivative.exercise_date: This option is fully vested.

SEC source: 0001209191-21-048228 · doc4.xml · derivative · entry 1

Schadt Eric · CIK 0001873468 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,564,847

Underlying: Class A Common Stock · 2,564,847 shares

Expires 2027-05-31

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F1 · derivative.exercise_date: This option is fully vested.

SEC source: 0001209191-21-048253 · doc4.xml · derivative · entry 3

Turner Nat · CIK 0001822293 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By NTWJ Holdings, LLC

Disclosed balance after: 166,666

Underlying: Class A Common Stock · 166,666 shares

Expires not disclosed

F2 · derivative.exercise_date: In connection with the consummation of the Business Combination, all of the private placement warrants of CMLS held by the Reporting Person, which previously entitled the Reporting Person to purchase one share of CMLS's Class A Common Stock at a price of $11.50 per whole share at any time commencing on the later of 12 months from the closing of CMLS's initial public offering or 30 days after the completion of an initial business combination of CMLS, were converted into private placement warrants of Issuer (each a "New Private Placement Warrant") simultaneously with the closing of the Business Combination, with each whole New Private Placement Warrant entitling the holder thereof to the right to purchase one share of Issuer's Class A Common Stock.

F2 · derivative.expiration_date: In connection with the consummation of the Business Combination, all of the private placement warrants of CMLS held by the Reporting Person, which previously entitled the Reporting Person to purchase one share of CMLS's Class A Common Stock at a price of $11.50 per whole share at any time commencing on the later of 12 months from the closing of CMLS's initial public offering or 30 days after the completion of an initial business combination of CMLS, were converted into private placement warrants of Issuer (each a "New Private Placement Warrant") simultaneously with the closing of the Business Combination, with each whole New Private Placement Warrant entitling the holder thereof to the right to purchase one share of Issuer's Class A Common Stock.

F3 · ownership.nature: The securities are held of record by NTWJ Holdings, LLC ("NTWJ"). Mr. Turner is a managing member of NTWJ. As such, Mr. Turner may be deemed to have beneficial ownership of such securities. Mr. Turner disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-21-048253 · doc4.xml · derivative · entry 2

Turner Nat · CIK 0001822293 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 25,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F1 · kind: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F1 · price: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F1 · derivative.exercise_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F1 · derivative.expiration_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

SEC source: 0001209191-21-048253 · doc4.xml · nonDerivative · entry 1

Turner Nat · CIK 0001822293 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

SEC source: 0001209191-21-048229 · doc4.xml · derivative · entry 1

White Karen Ann · CIK 0001874118 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,109

Underlying: Class A Common Stock · 206,109 shares

Expires 2030-12-21

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F1 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-048227 · doc4.xml · derivative · entry 3

Leproust Emily M. · CIK 0001753655 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,666

Underlying: Class A Common Stock · 166,666 shares

Expires not disclosed

F2 · kind: In connection with the consummation of the Business Combination, all of the private placement warrants of CMLS held by the Reporting Person, which previously entitled the Reporting Person to purchase one share of CMLS's Class A Common Stock at a price of $11.50 per whole share at any time commencing on the later of 12 months from the closing of CMLS's initial public offering or 30 days after the completion of an initial business combination of CMLS, were converted into private placement warrants of Issuer (each a "New Private Placement Warrant") simultaneously with the closing of the Business Combination, with each whole New Private Placement Warrant entitling the holder thereof to the right to purchase one share of Issuer's Class A Common Stock.

F2 · derivative.exercise_date: In connection with the consummation of the Business Combination, all of the private placement warrants of CMLS held by the Reporting Person, which previously entitled the Reporting Person to purchase one share of CMLS's Class A Common Stock at a price of $11.50 per whole share at any time commencing on the later of 12 months from the closing of CMLS's initial public offering or 30 days after the completion of an initial business combination of CMLS, were converted into private placement warrants of Issuer (each a "New Private Placement Warrant") simultaneously with the closing of the Business Combination, with each whole New Private Placement Warrant entitling the holder thereof to the right to purchase one share of Issuer's Class A Common Stock.

F2 · derivative.expiration_date: In connection with the consummation of the Business Combination, all of the private placement warrants of CMLS held by the Reporting Person, which previously entitled the Reporting Person to purchase one share of CMLS's Class A Common Stock at a price of $11.50 per whole share at any time commencing on the later of 12 months from the closing of CMLS's initial public offering or 30 days after the completion of an initial business combination of CMLS, were converted into private placement warrants of Issuer (each a "New Private Placement Warrant") simultaneously with the closing of the Business Combination, with each whole New Private Placement Warrant entitling the holder thereof to the right to purchase one share of Issuer's Class A Common Stock.

SEC source: 0001209191-21-048227 · doc4.xml · derivative · entry 2

Leproust Emily M. · CIK 0001753655 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 25,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F1 · kind: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F1 · price: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F1 · derivative.exercise_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F1 · derivative.expiration_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

SEC source: 0001209191-21-048227 · doc4.xml · nonDerivative · entry 1

Leproust Emily M. · CIK 0001753655 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

SEC source: 0001209191-21-048226 · doc4.xml · derivative · entry 1

Sherman Rachel E. · CIK 0001784705 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 363,223

Underlying: Class A Common Stock · 363,223 shares

Expires 2030-02-17

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F1 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-048224 · doc4.xml · derivative · entry 3

Prentice Anthony · CIK 0001873901 · Chief Product Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 196,666

Underlying: Class A Common Stock · 196,666 shares

Expires 2030-02-17

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F1 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-048224 · doc4.xml · derivative · entry 2

Prentice Anthony · CIK 0001873901 · Chief Product Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 449,871

Underlying: Class A Common Stock · 449,871 shares

Expires 2030-02-17

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F1 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001209191-21-048224 · doc4.xml · derivative · entry 1

Prentice Anthony · CIK 0001873901 · Chief Product Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,733,674

Underlying: Class A Common Stock · 1,733,674 shares

Expires 2027-09-30

F2 · price: Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

F1 · derivative.exercise_date: 6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.

SEC source: 0001213900-21-038789 · ownership.xml · derivative · entry 4

Casdin Eli · CIK 0001534264 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By CMLS Holdings LLC

Disclosed balance after: 0

Underlying: Class A Common Stock · 10,993,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F1 · kind: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F1 · derivative.exercise_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F1 · derivative.expiration_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F2 · ownership.nature: The securities are held of record by CMLS Holdings LLC ("CMLS Holdings"). CMLS Holdings LLC is the record holder of the Class A common stock and the Class A Common Stock exercisable upon the issuance of warrants reported herein. The Board of Managers of CMLS Holdings LLC is comprised of Mr. Casdin and Mr. Keith Meister who share voting and investment discretion with respect to the Class A common stock held of record by CMLS Holdings LLC. C-LSH LLC and M-LSH LLC are the members of CMLS Holdings LLC, and Messrs. Casdin and Meister are the managing members of C-LSH LLC and M-LSH LLC, respectively. As such, Mr. Casdin may be deemed to have or share beneficial ownership of the securities held directly by CMLS Holdings LLC. Each of C-LSH LLC and Mr. Casdin disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein.

SEC source: 0001213900-21-038789 · ownership.xml · derivative · entry 3

Casdin Eli · CIK 0001534264 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By CMLS Holdings LLC

Disclosed balance after: 6,736,669

Underlying: Class A Common Stock · 6,736,669 shares

Expires 2027-09-05

F4 · kind: Following the completion of the business combination, warrants to purchase Class A Common Stock become exercisable on September 5, 2021, the date that is one year after the closing of the IPO of Sema4's predecessor, CMLS.

F4 · price: Following the completion of the business combination, warrants to purchase Class A Common Stock become exercisable on September 5, 2021, the date that is one year after the closing of the IPO of Sema4's predecessor, CMLS.

F1 · derivative.expiration_date: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F2 · ownership.nature: The securities are held of record by CMLS Holdings LLC ("CMLS Holdings"). CMLS Holdings LLC is the record holder of the Class A common stock and the Class A Common Stock exercisable upon the issuance of warrants reported herein. The Board of Managers of CMLS Holdings LLC is comprised of Mr. Casdin and Mr. Keith Meister who share voting and investment discretion with respect to the Class A common stock held of record by CMLS Holdings LLC. C-LSH LLC and M-LSH LLC are the members of CMLS Holdings LLC, and Messrs. Casdin and Meister are the managing members of C-LSH LLC and M-LSH LLC, respectively. As such, Mr. Casdin may be deemed to have or share beneficial ownership of the securities held directly by CMLS Holdings LLC. Each of C-LSH LLC and Mr. Casdin disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein.

SEC source: 0001213900-21-038789 · ownership.xml · nonDerivative · entry 2

Casdin Eli · CIK 0001534264 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Casdin Partners Master Fund, LP

Disclosed balance after: 5,000,000

F3 · ownership.nature: The securities reflected as beneficially owned by Casdin Partners Master Fund, LP in the table above consists of 5,000,000 shares of Class A common stock. Such securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (iii) Mr. Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Mr. Casdin disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein.

SEC source: 0001213900-21-038789 · ownership.xml · nonDerivative · entry 1

Casdin Eli · CIK 0001534264 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By CMLS Holdings LLC

Disclosed balance after: 10,993,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: In connection with the closing (the "Closing") of the business combination (the "Business Combination") between the Issuer (which was formerly known as CM Life Sciences, Inc. or "CMLS") and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), among other things, each share of CMLS's Class B common stock converted pursuant to the terms of such stock into shares of the Issuer's Class A Common Stock on a one-for-one basis.

F2 · ownership.nature: The securities are held of record by CMLS Holdings LLC ("CMLS Holdings"). CMLS Holdings LLC is the record holder of the Class A common stock and the Class A Common Stock exercisable upon the issuance of warrants reported herein. The Board of Managers of CMLS Holdings LLC is comprised of Mr. Casdin and Mr. Keith Meister who share voting and investment discretion with respect to the Class A common stock held of record by CMLS Holdings LLC. C-LSH LLC and M-LSH LLC are the members of CMLS Holdings LLC, and Messrs. Casdin and Meister are the managing members of C-LSH LLC and M-LSH LLC, respectively. As such, Mr. Casdin may be deemed to have or share beneficial ownership of the securities held directly by CMLS Holdings LLC. Each of C-LSH LLC and Mr. Casdin disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein.